Extension Study of the U-LaserPrint-1 Clinical Trial

Brief summary (registry, in English)

To collect additional data to evaluate the long-term safety of the InvivoLPrint-U therapy (a combination of bioprinted cultured autologous urothelial cells and their administration using the corresponding bioprinter) in the context of neobladder reconstruction surgery conducted as part of the U-LaserPrint-1 clinical trial.

What you commit to

• Study type: Interventional · Phase 1/2
• Planned participants: 6
• 2 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who finished the U-LaserPrint-1 trial and had bladder reconstruction. It follows them over time to check the long-term safety of InvivoLPrint-U.

Age

18 years or older

Sex

All sexes can join

Disease stage

Muscle-invasive bladder cancer, with a new bladder built after bladder removal surgery (as in the U-LaserPrint-1 trial)

Earlier treatment

Must have taken part in and finished the U-LaserPrint-1 clinical trial

Main reasons for not taking part

• Refusing to take part in the extension study
• Not following the procedures of the U-LaserPrint-1 trial
• Being unable to follow the follow-up requirements of the extension study

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details